Triple-Drug cocktail aims to shrink head and neck tumors
Disease control
Not yet recruiting
This study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy helps people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 with cancer that has spread…
Phase 3 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC